Shares of Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) have been assigned a consensus rating of “Buy” from the six research firms that are currently covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating on the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $18.75.
Several research analysts recently weighed in on the stock. BidaskClub upgraded shares of Marinus Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday, December 30th. Laidlaw assumed coverage on shares of Marinus Pharmaceuticals in a research report on Thursday, December 14th. They issued a “buy” rating and a $18.00 price objective on the stock. HC Wainwright assumed coverage on Marinus Pharmaceuticals in a research note on Thursday, February 15th. They issued a “buy” rating and a $33.00 target price for the company. Finally, Mizuho assumed coverage on Marinus Pharmaceuticals in a research note on Monday, March 19th. They issued a “buy” rating and a $13.00 target price for the company.
MRNS stock opened at $4.75 on Friday. Marinus Pharmaceuticals has a 1-year low of $1.13 and a 1-year high of $9.87.
Marinus Pharmaceuticals (NASDAQ:MRNS) last posted its quarterly earnings data on Tuesday, March 6th. The biopharmaceutical company reported ($0.20) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.13) by ($0.07).
In other Marinus Pharmaceuticals news, CEO Christopher Michael Cashman sold 9,566 shares of the company’s stock in a transaction that occurred on Thursday, January 18th. The stock was sold at an average price of $6.28, for a total value of $60,074.48. Following the completion of the sale, the chief executive officer now owns 247,903 shares of the company’s stock, valued at $1,556,830.84. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 4.60% of the stock is owned by corporate insiders.
Institutional investors and hedge funds have recently modified their holdings of the business. Bank of New York Mellon Corp purchased a new stake in Marinus Pharmaceuticals in the third quarter worth approximately $128,000. FNY Partners Fund LP purchased a new stake in shares of Marinus Pharmaceuticals during the fourth quarter valued at approximately $183,000. Wells Fargo & Company MN purchased a new stake in shares of Marinus Pharmaceuticals during the fourth quarter valued at approximately $225,000. Goldman Sachs Group Inc. purchased a new stake in shares of Marinus Pharmaceuticals during the fourth quarter valued at approximately $305,000. Finally, Virtus Fund Advisers LLC purchased a new stake in shares of Marinus Pharmaceuticals during the fourth quarter valued at approximately $308,000. 63.49% of the stock is owned by institutional investors and hedge funds.
WARNING: This piece of content was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece of content on another publication, it was illegally stolen and republished in violation of US & international trademark & copyright legislation. The original version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/04/13/marinus-pharmaceuticals-inc-mrns-given-average-recommendation-of-buy-by-analysts.html.
About Marinus Pharmaceuticals
Marinus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical stage product candidate, ganaxolone, is an allosteric modulator of GABAA, developed in three different dose forms: intravenous (IV), capsule, and liquid.
Receive News & Ratings for Marinus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.